Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hizentra Weekly vs Biweekly Dosing in Immune Deficiency
NCT02711228Phase 4Completed
- Sponsor
- CSL Limited
- Start
- Mar 2016
- Primary completion
- Jan 2018
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of IgPro10 in primary immunodeficiency (PI), secondary immune deficiency (SID), sponsored by CSL Limited. Started Mar 2016; status: completed.
02
Drugs
IgPro10
03
Conditions
primary immunodeficiency (PI)secondary immune deficiency (SID)
Beyond the preview
Go deeper on NCT02711228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711228.